Large Inflow of Money Detected in Nevro

Nevro (NVRO) : Thursdays money flow indicated an uptick to downtick ratio was at 1.45. The total value of inflow transactions on upticks was $8.83 million, whereas, the total value of outflow trades on downticks was $6.11 million. The total money flow was $2.73 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $4.67 million. The total value of the trades done on upticks was $4.67 million. Nevro (NVRO) was trading with a -0.09% change over previous days close. It fell $0.07 during the day and reached $79.28. The stock was 1.3% compared to the previous weeks close.


The stock has recorded a 20-day Moving Average of 7.95% and the 50-Day Moving Average is 13.3%. Shares have rallied 59.14% from its 1 Year high price. On Jul 11, 2016, the shares registered one year high at $80.06 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $72.57 and the 200 Day Moving Average price is recorded at $64.25.

Nevro (NYSE:NVRO): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $79.67 and $78.90 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $79.89, notching a gain of 0.68% for the day. The total traded volume was 516,733 . The stock had closed at $79.35 on the previous day.

In an insider trading activity, Enxing Michael, officer (VP of Sales) of Nevro Corp, unloaded 1,500 shares at an average price of $75.52 on July 5, 2016. The total amount of the transaction was worth $113,280, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Companys Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Companys Senza system creates electrical impulses from two hertz to 10 kilohertz, including its HF10 therapy, which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *